Literature DB >> 8549295

Resistance among important pathogens and the antimicrobial activity of parenteral fluoroquinolones at 43 US medical centres.

R N Jones1, E N Kehrberg, M E Erwin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8549295     DOI： 10.2165/00003495-199500492-00033

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  5 in total

1.  Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a Multicenter, National Comparative Activity Surveillance Study. The Ofloxacin Surveillance Group.

Authors:  R N Jones; L B Reller; L A Rosati; M E Erwin; M L Sanchez
Journal:  Diagn Microbiol Infect Dis       Date:  1992-07       Impact factor: 2.803

Review 2.  Inactivation of antibiotics and the dissemination of resistance genes.

Authors:  J Davies
Journal:  Science       Date:  1994-04-15       Impact factor: 47.728

3.  Multiple-antibiotic-resistant pathogenic bacteria. A report on the Rockefeller University Workshop.

Authors:  A Tomasz
Journal:  N Engl J Med       Date:  1994-04-28       Impact factor: 91.245

4.  North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group.

Authors:  R N Jones; D J Hoban
Journal:  Diagn Microbiol Infect Dis       Date:  1994-01       Impact factor: 2.803

5.  The North American component (the United States and Canada) of an International Comparative MIC trial monitoring ofloxacin resistance.

Authors:  D J Hoban; R N Jones; L J Harrell; M Knudson; D Sewell
Journal:  Diagn Microbiol Infect Dis       Date:  1993 Aug-Sep       Impact factor: 2.803
  5 in total
  2 in total

Review 1.  Quinolones: which generation for which microbe?

Authors:  M K Lee; M S Kanatani
Journal:  West J Med       Date:  1999-06

2.  In vitro activity of fleroxacin against multiresistant gram-negative bacilli isolated from patients with nosocomial infections.

Authors:  M Araque; E Velazco
Journal:  Intensive Care Med       Date:  1998-08       Impact factor: 17.440
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.